SLC2A1 and breast carcinoma: GLUT1 inhibitors such as WZB117 have been reported to sensitize or increase efficacy of traditional therapeutics including adriamycin (doxorubicin) and radiotherapy for breast cancer (Chen et al., 2017; Zhao et al., 2016).